Xu Diyong purchased $15.0M of QTTB (indirect holdings)

Xu Diyong purchased 1,875,000 indirectly-held shares of Q32 Bio Inc. (QTTB) at $8.00 ($15.00M total) across 2 trades on 2026-05-28.

Original reporting
SEC EDGAR · Xu Diyong
Published Jun 2, 2026, 1:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QTTB
Bullish
high confidence
Mentioned
$QTTB
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QTTBBullishMed
01

Why it matters

The director's $15M purchase is a fresh, material event that could influence short‑term price dynamics.

02

Market read

Insider buying is a classic bullish signal, especially from a major shareholder, and may attract short‑term traders.

03

What to watch

No pre‑arranged 10b5‑1 plan; the buy was discretionary, which may indicate private information.

Relevance 8/10Novelty 7/10Timing: today

Background

SEC Form 4 filing discloses an insider transaction for Q32 Bio Inc.

Company-level read

Ticker impact

$QTTBBullishHigh confidence
Context

Director and 10% owner Xu Diyong bought 1.875M shares for $15M, increasing his stake to 625,000 shares.

Expected impact

likely upward pressure as the market prices in the insider buy.

Evidence & confidence

A $15M open‑market purchase by a director/10% owner is material and signals confidence.

Market effects

May boost sentiment in the biotech sector as insider confidence is viewed positively.

Limited to U.S. markets where QTTB trades.

Low global impact beyond the company's niche.

Counterpoint

The purchase could be a defensive move to lock in shares before a potential downside.

Key entities

  • Q32 Bio Inc.

    Biotech firm (ticker QTTB) subject of the insider purchase.

  • Xu Diyong

    Director and 10% owner of Q32 Bio Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QTTBMedAI 8/10

Q32 Bio Reports Q3 Results; Advances Bempikibart Toward Phase 3 In Alopecia Areata

Q32 Bio (QTTB) reported Q3 2026 results, with R&D expenses rising to $5.1M and net loss increasing to $8.9M. The company presented Phase 2a trial data for bempikibart, showing a 35.3% mean reduction in SALT scores for alopecia areata patients. Q32 Bio plans to initiate a Phase 3 trial in early 2027 and has $289.6M in cash reserves. The stock is currently trading at $8.81, up 0.57%.

$QTTBLow

Q32 Bio 3Q 2026: Net loss $8.9M, EPS $(0.26) — 10-Q Summary

Q32 Bio reported a Q3 2026 net loss of $8.9M, up 20.7% YoY, with EPS loss narrowing to $0.26. The company's bempikibart study showed improved SALT scores and no serious adverse events. Q32 plans regulatory discussions in Q4 2026 and aims to advance bempikibart in early 2027. Akebia will develop ADX-097 after the asset sale.

$QTTBMedAI 8/10

Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Q32 Bio reported Q3 2026 results, highlighting positive SIGNAL-AA clinical trial data for bempikibart, a treatment for alopecia areata. The company presented 36-week results and 16-week off-drug findings at EADV Congress, showing durable responses. Q32 Bio plans to initiate a registration-directed program in 1H 2027 and has $289.6M in cash. The company also strengthened its leadership team and expects Phase 3 topline results from the planned program.